ストックスクリーナーアプリを入手
1.51
4.86%
0.07
アフターアワーズ：
1.53
0.02
+1.32%
前日終値:
$1.44
開ける：
$1.35
24時間の取引高:
851.95K
Relative Volume:
3.29
時価総額：
$793.29K
収益：
-
当期純損益:
$-8.26M
株価収益率:
-0.0282
EPS:
-53.609
ネットキャッシュフロー:
$-12.17M
1週間 パフォーマンス:
-65.42%
1か月 パフォーマンス:
-78.52%
6か月 パフォーマンス:
-75.19%
1年 パフォーマンス:
-98.72%
1日の値動き範囲:
$1.21
$1.70
1週間の範囲:
$1.21
$11.12
52週間の値動き範囲:
$1.21
$130.39
Gri Bio Inc Stock (GRI) Company Profile
GRI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.51 | 793.29K | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-09 | 開始されました | H.C. Wainwright | Buy |
Gri Bio Inc (GRI) 最新ニュース
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - MSN
Gri Bio Announces Closing Of $5.0 Million Public Offering - MarketScreener
GRI Bio Announces Closing of $5.0 Million Public Offering - GlobeNewswire
GRI Bio Raises $5M, Eyes $18.3M Total Potential for Breakthrough Autoimmune Treatment - Stock Titan
GRI Bio Shares Rebound In After-Hours Trading - Stocks Telegraph
GRI Bio (GRI) Reports Positive Interim Safety Results for IPF Tr - GuruFocus
Street can a-GRI on phase IIb safety win in IPF with tazarotene - BioWorld MedTech
GRI Bio Announces $5 Million Public Offering Amid Market Decline - Nasdaq
GRI Bio Prices up to $13 Million Equity Offering - MarketScreener
GRI Bio announces $5 million public offering - Investing.com India
GRI Bio announces $5 million public offering By Investing.com - Investing.com Australia
GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewswire
GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More - Stock Titan
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s IPF drug shows promise in early trial By Investing.com - Investing.com South Africa
GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621 - TipRanks
GRI Bio’s IPF drug shows promise in early trial - Investing.com
Gri Bio IncIDMC Recommends Continuation Of Study With No Safety Concerns - MarketScreener
GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire
Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment - Stock Titan
GRI Bio secures global patents for NKT cell modulators By Investing.com - Investing.com South Africa
GRI Bio secures global patents for NKT cell modulators - Investing.com
GRI Bio announces the granting of two global patents for Europe, Japan - TipRanks
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire
Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval - Stock Titan
Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 By Investing.com - Investing.com South Africa
Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 - Investing.com India
Pre-market Movers: PSTX, HOOK, MDAI, ALEC... - RTTNews
GRI Bio (GRI) to Release Quarterly Earnings on Thursday - Defense World
GRI Bio Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire
GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter - StockTitan
GRI Bio expects cash to fund operations into Q2 of 2025 - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI stock touches 52-week low at $5.12 amid market fluctuations - Investing.com
GRI Bio, Inc. Anticipates Key Phase 2a Data Readouts for GRI-0621 in 2025 While Securing Cash Runway for Operations - Nasdaq
GRI Bio Reports Full Year 2024 Financial Results and - GlobeNewswire
GRI Bio's IPF Treatment Shows Promise: Key Clinical Data Coming in 2025 - StockTitan
GRI Bio, Inc. SEC 10-K Report - TradingView
GRI Bio regains compliance with Nasdaq minimum bid rule By Investing.com - Investing.com Australia
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire
GRI Bio Back In Compliance With Nasdaq Minimum Bid Rule - Nasdaq
GRI Bio regains compliance with Nasdaq minimum bid rule - Investing.com India
GRI Bio, Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule - Nasdaq
2 ETFs That Are Surging While U.S. Stocks Are Slumping - The Globe and Mail
Meta Stock: The Potential and Pitfalls of Its Reality Labs Bet - The Globe and Mail
Stock market today: Wah Fu Education Group +219.55%, Jet.AI +46.26% among top gainers in early trading - Business Upturn
GRI Bio announces 1-for-17 reverse stock split to regain Nasdaq compliance - MSN
GRI Bio Announces Reverse Stock Split - The Manila Times
GRI Bio Stock Set to Reverse Split on Monday, February 24th (NASDAQ:GRI) - Defense World
Can GRI Bio's 17:1 Reverse Split Save Its Nasdaq Listing? Key Details Revealed - StockTitan
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Gri Bio Inc (GRI) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):